X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Harnessing the power of real-world evidence to benefit patients through PDUFA VI

By Andrew Powaleny  |    September 6, 2016
America’s biopharmaceutical researchers are in a golden era of medical research, discovery and development for patients. Rapid advances in technology and science have enhanced our ability to use...   Read More

Improving FDA’s combination product review process could increase epinephrine auto-injector competition

By Stephen J. Ubl  |    August 30, 2016
Combination products that consist of a medicine and delivery device are important treatment options for patients and have the potential to improve public health. Innovator companies invest in...   Read More

In biopharmaceutical research, if at first you don’t succeed, try again

By Andrew Powaleny  |    August 17, 2016
In case you missed it, an article in STAT News today profiles setbacks inside the process of researching new treatments and cures for patients. For America’s biopharmaceutical research companies,...   Read More

Dr. George Scangos: Not just science for science’s sake

By Andrew Powaleny  |    August 10, 2016
America’s biopharmaceutical researchers are working tirelessly to develop new and innovative medicines for patients. For those diseases that have no treatment options, the opportunity to improve...   Read More

What you need to know about PDUFA VI

By Andrew Powaleny  |    July 27, 2016
The U.S. Food and Drug Administration (FDA) recently released its performance goals letter for the sixth installment of the Prescription Drug User Fee Act (PDUFA). The letter comes after months of...   Read More

Science of Hope: Learning from setbacks

By Andrew Powaleny  |    June 20, 2016
America’s biopharmaceutical research companies are committed to developing new treatments and cures that improve health and save patient lives. Jen O’Neil, principal oncology scientist at Merck,...   Read More

Advancing the science of hope

By Andrew Powaleny  |    June 13, 2016
Developing new medicines is a challenging undertaking, and the science is only getting harder. As our understanding of science grows, so does the complexity of developing new medicines,...   Read More

Cost of mental illness underscores need for new treatments

By Holly Campbell  |    May 25, 2016
Today, one in five American adults and children experience a mental illness in any given year. As the prevalence of complex mental health conditions has grown, the cost of caring for patients has...   Read More

Fighting blood cancers together at the 2016 Leukemia Ball

By Josephine Martin  |    March 11, 2016
Tomorrow, the Leukemia & Lymphoma Society (LLS) will hold one of Washington, D.C.’s largest charitable events: the 2016 Leukemia Ball. Since it began in 1988, the annual event has raised nearly...   Read More

FDA approves a record 45 new medicines in 2015

By Holly Campbell  |    January 11, 2016
Last year was an exceptionally strong year for biopharmaceutical innovation as the U.S. Food and Drug Administration (FDA) approved 45 new medicines – the highest number of approvals in almost two...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates